Navigation Links
Douglas Harrington, MD Addresses Select Group Of Physicians Regarding Latest Advances In Cardiovascular Risk Assessment
Date:3/19/2013

SAN FRANCISCO, March 19, 2013 /PRNewswire/ -- Aviir Inc., a biotechnology company dedicated to enhanced detection and prevention of cardiovascular disease through innovative diagnostic tests, announced that Douglas Harrington , MD, Clinical Professor of Pathology at USC and Aviir Inc. CEO, addressed a select group of physicians and leading cardiologists on the Latest Advances in Cardiovascular Risk Assessment at a special invitation-only reception in San Francisco. The event took place March 10, during the American College of Cardiology (ACC) 2013 Annual Conference and included guest speakers Thomas Quertermous , PhD, Professor of Cardiovascular Medicine from the Stanford University School of Medicine, and Americo Simonini , MD, Cardiologist at Cedars-Sinai Medical Center.

(Logo: http://photos.prnewswire.com/prnh/20130319/LA79677LOGO)

"Our goal is to present and discuss the best cardiac risk assessment methods available. Presenting next generation tests like MIRISK VP™ with fellow physicians in an intimate forum enabled a free exchange and the chance to discuss advances in the field of preventative cardiology," said Dr. Harrington.

Many physicians at the event elected to take the MIRISK VP test on-site, which was offered by GUARDaHEART, a national non-profit dedicated to heart disease awareness and prevention.

MIRISK VP stratifies the intermediate risk group, which has proven to be a critical part of risk assessment, as most adverse cardiac events happen to intermediate risk individuals. In fact, MIRISK VP was shown in a peer-reviewed publication to significantly improve cardiac risk assessment by reclassifying intermediate risk individuals to either high or low risk groups, resulting in a net reclassificat
'/>"/>

SOURCE Aviir Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
2. Aviir, Inc.s CEO Dr. Douglas Harrington Delivered The Facts Surrounding Heart Disease At The Los Angeles Ultimate Womens Expo
3. Dr. James Douglas Adds Human Growth Hormone (HGH) Therapy to IVF Protocols for Poor Responding Patients
4. Sequenom Addresses Preliminary Injunction Decision, Reaffirms Defense of Patent
5. inVentiv Health Selected to Provide Sales Operations Support for Santarus
6. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
7. Webcor Builders Selected as the General Contractor for First Phase of LA BioMeds New Campus Master Plan
8. Sequenom Named to NASDAQ Global Select Market
9. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
10. First Choice Rehabilitation Specialists Joins Select Medical
11. Netsmart Selects Overland Park, Kansas, for New Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , ... July 31, 2015 , ... Ralco is honored ... at the Lyon County Fair to be held August 5-9 in Marshall. The Ralco ... their meals come from and how agriculture impacts their daily lives. This unique exhibit ...
(Date:7/30/2015)... -- According to a new market research ... PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), by ... End Users - Global Forecast to 2020", published by ... 2,107.99 million by 2020 from USD 1,034.93 million in ... Browse more than 75 market ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/29/2015)... , July 30, 2015 ... results for the second quarter of 2015. CEO ... results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered ... results - Performance drivers ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... In the smooth, white, bunny-suited clean-room world of silicon wafers ... may go a long way, perhaps all the way to ... Their research shows that light ricocheting around inside the ... film is ultra thin. A film that,s nanoscale-thin and has ...
... Decision Resources, one of the world,s leading research and ... owing to increasing generic availability of antihypertensive agents, the ... 2009 to $23 billion in 2019 in the United ... The Pharmacor 2010 findings from the topic ...
... Enters into Share Transfer Agreement -- SHENZHEN, China, Sept. 28 /PRNewswire-Asia-FirstCall/ -- ... ... lpUnit=,PRN,; --> ... = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Biology Technology:Solar cells thinner than wavelengths of light hold huge power potential 2Solar cells thinner than wavelengths of light hold huge power potential 3Due to Generic Erosion, the Hypertension Drug Market Will Decline by $3 Billion from 2009 to 2019 2Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 2Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 3Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 4Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 5Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 6Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 7Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 8
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
(Date:7/9/2015)... PLEASANTON, Calif. , July 9, 2015 /PRNewswire/ ... tools, today announcing its acquisition of Avid Nano. ... dynamic light scattering (DLS) systems.    ... world,s smallest, fastest and easiest to use protein ... system that measures a protein,s hydrodynamic size, size ...
(Date:7/8/2015)... , N.J. and NEW YORK , July ... Guidepoint today announced BD & Guidepoint ... companies with free access to Guidepoint,s expert network services. ... that are developing cutting-edge technologies to improve healthcare delivery ... Guidepoint research manager, each start-up entrepreneur will be able ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... 2003 epidemic of Highly Pathogenic Avian Influenza (HPAI) in ... in the developed world. Gert-Jan Boender and colleagues have ... model which can predict the probability of infection from ... identify high-risk areas in the Netherlands and analyze various ...
... more bacteria are antibiotic resistant and because antibiotics are ... to developing new antibacterial strategies, taken by researchers from ... amount of iron (Fe), which is critical for bacterial ... study, which appears online on March 15 in advance ...
... Pennsylvania School of Medicine have discovered that an enzyme ... that is defective in cystic fibrosis patients. The disruption ... to airways causes thick mucus to buildup inside the ... treating lung infections in some cystic fibrosis (CF) patients. ...
Cached Biology News:Penn study on lung-infecting bacterial enzyme suggests new approach to cystic fibrosis treatment 2
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
... its effects by binding ... a disulfide-linked heterotetrameric protein ... subunits and two Beta ... following configuration: Beta-Alpha-Alpha-Beta. ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Mfr ...
... 11, Compliant software for JASCO HPLC systems. , Integrated Instrument ... EZChrom Elite ... options for JASCO HPLC systems. This provides a completely integrated system ... settings with each run. , ...
Biology Products: